Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of insider share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by several executives on March 9, 2011, at a price of £11.92 per share through the Company's Share Reward Plan. Transactions included both personal contributions (partnership element) and company contributions (matching element). No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of specific share purchases by named individuals.
Important Facts for Investors
- Transaction Date: March 9, 2011.
- Share Price: £11.92 per Ordinary share.
- Participants: Mr A P Witty, Mr J S Heslop, Mr S M Bicknell, Mr E J Gray, Mr D S Redfern, Ms C Thomas, Dr P J T Vallance, and Mrs V A Whyte.
- Transaction Type: Acquisitions under the Share Reward Plan (both personal and company-matched shares).
- Disclosure Rule: Notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).